Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Tvardi Therapeutics, Inc. is a biotechnology firm focused on developing novel therapies for cancer treatment, particularly leveraging its proprietary small molecule platform targeting the STAT3 pathway. The company operates primarily in the United States and is in the clinical trial phase for its lead candidate, TVB-2640, which aims to address unmet medical needs in oncology.
Tvardi Therapeutics currently does not generate revenue as it is in the clinical development stage. The company aims to monetize its pipeline through eventual product sales and partnerships with larger pharmaceutical companies. Its competitive advantage lies in its unique approach to targeting the STAT3 pathway, which is implicated in various cancers, potentially allowing for differentiated therapeutic options.
Progress in clinical trials for TVB-2640, particularly Phase 2 results expected in late 2026
Partnership announcements with larger pharmaceutical companies for drug development
Regulatory approvals from the FDA for clinical trials or eventual commercialization
Market sentiment regarding the oncology therapeutic landscape
Regulatory changes affecting drug approval processes
Technological disruption in cancer treatment methodologies
Emergence of alternative therapies targeting the same cancer pathways
Increased competition from larger pharmaceutical companies with more resources
High cash burn rate due to ongoing clinical trials without revenue generation
Dependence on external funding sources for operational sustainability
low - As a biotechnology firm focused on oncology, Tvardi's performance is less sensitive to economic cycles compared to consumer discretionary sectors, though funding availability can be influenced by broader economic conditions.
Moderate - Rising interest rates could increase the cost of capital for funding clinical trials, potentially impacting the company's ability to finance its operations and development pipeline.
minimal - The company has a very low debt-to-equity ratio, indicating limited reliance on credit markets.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector may find Tvardi appealing due to its innovative pipeline.
high - The stock is likely to exhibit high volatility due to the binary nature of clinical trial outcomes.